Table of Contents

• 1.   Market Introduction

  •   1. Objectives of the Study
      2. Market Definition
      3. Market Scope
       3.1. Years Considered for the Study
       3.2. Market Covered
      4. Currency
      5. Limitations
      6. Stakeholders

• 2.   Research Methodology

  •   1. Research Data
       1.1. Secondary Data
        1.1.1. Key Data from Secondary Sources
       1.2. Primary Data
        1.2.1. Key Data from Primary Sources
      2. Market Size Estimation
      3. Market Breakdown and Data Triangulation
      4. Assumptions for the Study

• 3.   Executive Summary
  •   1. Market Outlook
      2. Segment Outlook
      3. Competitive Insights
    
• 4.   China Oncology Drugs Market Variables, Trends and Scope

  •   1. Market Lineage Outlook
      2. Penetration and Growth Prospect Mapping
      3. Industry Value Chain Analysis
      4. Cost Analysis Breakdown
      5. Technology Overview
      6. Regulatory Framework
       6.1. Reimbursement Framework
       6.2. Standards and Compliances

• 5.   Market Overview
  •   1. Market Dynamics
       1.1. Market Driver Analysis
        1.1.1. Increasing focus of China Oncology Drugs Companies on Brand Protection
        1.1.2. Untapped Opportunities in Emerging Regions
       1.2. Market Restraint Analysis
        1.2.1. High Cost Associated with Implementation of Predictive Analysis
       1.3. Industry Challenges
        1.3.1. Presence of Ambiguous Regulatory Framework
    
• 6.   China Oncology Drugs Market Analysis Tools
  •   1. Industry Analysis - Porter’s
       1.1. Supplier Power
       1.2. Buyer Power
       1.3. Substitution Threat
       1.4. Threat from New Entrants
       1.5. Competitive Rivalry
      2. Pestel Analysis
       2.1. Political Landscape
       2.2. Environmental Landscape
       2.3. Social Landscape
       2.4. Technology Landscape
       2.5. Legal Landscape
      3. Major Deals And Strategic Alliances Analysis
       3.1. Joint Ventures
       3.2. Mergers and Acquisitions
       3.3. Licensing and Partnership
       3.4. Technology Collaborations
       3.5. Strategic Divestments
      4. Market Entry Strategies
      5. Case Studies
    
• 7.   China Oncology Drugs Market, By Drug Class Type Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Chemotherapy
      2. Targeted Therapy
      3. Immunotherapy Therapy
      4. Hormonal Therapy

• 8.   China Oncology Drugs Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)

  •   1. Blood Cancer
      2. Breast Cancer
      3. Gastrointestinal Cancer
      4. Prostate Cancer
      5. Lung Cancer
      6. Skin Cancer
      7. Ovarian Cancer
      8. Cervical Cancer
      9. Kidney Cancer
      10. Other Cancers

• 9.   Market Share Analysis and Competitive Landscape
  •   1. China Landscape - Key Players, Revenue and Presence
      2. China Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
      3. China Emerging Companies
      4. China - Market Share Analysis and Key Regional Players
      5. China Key Player - Growth Matrix
    
• 10.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

  •   1. AbbVie Inc.
       1.1. Company Overview
       1.2. Product Portfolio
       1.3. SWOT Analysis
       1.4. Financial Overview
       1.5. Strategic Overview
      2. Astellas Pharma Inc.
       2.1. Company Overview
       2.2. Product Portfolio
       2.3. SWOT Analysis
       2.4. Financial Overview
       2.5. Strategic Overview
      3. AstraZeneca PLC
       3.1. Company Overview
       3.2. Product Portfolio
       3.3. SWOT Analysis
       3.4. Financial Overview
       3.5. Strategic Overview
      4. Bristol-Myers Squibb Company
       4.1. Company Overview
       4.2. Product Portfolio
       4.3. SWOT Analysis
       4.4. Financial Overview
       4.5. Strategic Overview
      5. Celgene Corporation
       5.1. Company Overview
       5.2. Product Portfolio
       5.3. SWOT Analysis
       5.4. Financial Overview
       5.5. Strategic Overview
      6. F. Hoffmann-La Roche Ltd.
       6.1. Company Overview
       6.2. Product Portfolio
       6.3. SWOT Analysis
       6.4. Financial Overview
       6.5. Strategic Overview
      7. Johnson and Johnson
       7.1. Company Overview
       7.2. Product Portfolio
       7.3. SWOT Analysis
       7.4. Financial Overview
       7.5. Strategic Overview
      8. Shanghai Junshi Biosciences Co., Ltd.
       8.1. Company Overview
       8.2. Product Portfolio
       8.3. SWOT Analysis
       8.4. Financial Overview
       8.5. Strategic Overview
      9. Beigene
       9.1. Company Overview
       9.2. Product Portfolio
       9.3. SWOT Analysis
       9.4. Financial Overview
       9.5. Strategic Overview
      10. Jiangsu Hengrui Medicine Co., Ltd.
       10.1. Company Overview
       10.2. Product Portfolio
       10.3. SWOT Analysis
       10.4. Financial Overview
       10.5. Strategic Overview
      11. Pfizer Inc.
       11.1. Company Overview
       11.2. Product Portfolio
       11.3. SWOT Analysis
       11.4. Financial Overview
       11.5. Strategic Overview
      12. GlaxoSmithKline plc
       12.1. Company Overview
       12.2. Product Portfolio
       12.3. SWOT Analysis
       12.4. Financial Overview
       12.5. Strategic Overview

• 11.   Pre and Post COVID-19 Impact

  •   1. Positive influence on the healthcare industry
      2. The financial disruption of the manufacturing sector
      3. Impact of COVID-19 on emerging companies
      4. Significant mandates in the healthcare regulations initiated
    by administrations
      5. The overall economic slowdown of the developing and developed nations

• 12.   FutureWise SME Key Takeaway Points for Client